ClinicalTrials.gg
CompletedNCT02691494Updated Jul 13, 2021Results posted

Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women (Replicate Study)

A Phase 3 interventional study of Elagolix and Placebo for Estradiol/Norethindrone Acetate in Uterine Fibroids and Heavy Menstrual Bleeding, sponsored by AbbVie. Completed at 105 sites in 2 countries. Open to female participants aged 18 Years to 51 Years. Per ClinicalTrials.gov, last updated 2021-07-13.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
378
Allocation
Randomized
Ages
18 Years to 51 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 33 studies in Leiomyoma by AbbVie — none open to participants now, none under way, none of them phase 3. Leiomyoma · AbbVie.

Enrollment
6th of 28
378 · median 61
Started
2016
with 2 others
Phase 3
14 of 33
none open now
Registered
25th of 33
by date

Among the 33 studies in Leiomyoma by AbbVie, this one is the 6th largest by enrollment of the 28 interventional ones that give a count, is one of 3 that started in 2016, is one of 14 in phase 3, and was the 25th registered.

Leiomyoma

438 studies on the registry are indexed under Leiomyoma; 74 are open to participants now.

Browse Leiomyoma studies →

Open to participants now

None of the 33 studies in Leiomyoma by AbbVie is open now. The open studies under Leiomyoma, anywhere →

Who these studies take

Of the 44 Leiomyoma studies recruiting now, 22 (50%) set no upper age limit and 21 (48%) stop at 75 or younger; 4 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 51 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 33 studies in Leiomyoma by AbbVie as a file.
02

Study summary

This study seeks to evaluate the efficacy, safety and tolerability of elagolix alone and in combination with estradiol/norethindrone acetate for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.

03

Conditions studied

  • Uterine Fibroids
  • Heavy Menstrual Bleeding

Keywords

  • Elagolix
  • Elagolix Sodium
  • Heavy uterine bleeding
  • Heavy menstrual bleeding (HMB)
  • Leiomyomata
  • Menorrhagia
  • ABT-620
  • Elagolix + E2/NETA (Elagolix + Norethindrone acetate)
04

Who can participate

Ages eligible
18 Years to 51 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is a premenopausal female at the time of Screening.
  • Subject has a diagnosis of uterine fibroids documented by a pelvic ultrasound (transabdominal ultrasound/transvaginal ultrasound).
  • Subject has heavy menstrual bleeding associated with uterine fibroids as evidenced by menstrual blood loss > 80 mL during each of two screening menses as measured by the alkaline hematin method.
  • Subject has negative urine and/or serum pregnancy test in Screening and just prior to first dose.
  • Subject has an adequate endometrial performed during Screening, the results of which show no endometrial pathology.

Exclusion criteria

Exclusion Criteria:

  • Subject has screening pelvic ultrasound or saline infusion sonohysterography results that show a gynecological disorder.
  • Subject has history of osteoporosis or other metabolic bone disease.
  • Subject has clinically significant abnormalities in clinical chemistry, hematology, or urinalysis.
  • Subject has a history of major depression or post-traumatic stress disorder (PTSD) within 2 years of screening, OR a history of other major psychiatric disorder at any time (e.g., schizophrenia, bipolar disorder).
  • Subject is using any systemic for over 14 days within 3 months prior to Screening or is likely to require treatment with systemic corticosteroids during the course of the study. Over the counter and prescription topical, inhaled, intranasal or injectable (for occasional use) corticosteroids are allowed.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
378 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo for both elagolix twice daily (BID) and norethindrone acetate (E2/ NETA) once daily (QD)

    Drug: Placebo for Estradiol/Norethindrone Acetate · Drug: Placebo for Elagolix

  • Experimental
    Elagolix

    Elagolix 300 mg BID and placebo for E2/NETA (estradiol 1.0 mg/norethindrone acetate 0.5 mg) QD

    Drug: Elagolix · Drug: Placebo for Estradiol/Norethindrone Acetate

  • Experimental
    Elagolix + E2/NETA

    Elagolix 300 mg BID and E2/NETA (estradiol 1.0 mg/norethindrone acetate 0.5 mg) QD

    Drug: Elagolix · Drug: Estradiol/Norethindrone Acetate

Interventions

  • Film-coated tablets

    Also known as: ABT-620, elagolix sodium

  • DrugPlacebo for Estradiol/Norethindrone Acetate

    Placebo capsules

  • DrugEstradiol/Norethindrone Acetate

    Drug pages: Estradiol · Norethindrone Acetate

    Commercially-available E2/NETA tablets were over-encapsulated to maintain study blinding.

    Also known as: E2/NETA

  • DrugPlacebo for Elagolix

    Film-coated placebo tablets

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Meeting the Criteria for Responder

    Percentage of responders, defined as participants who met the following conditions: * Menstrual blood loss (MBL) volume \< 80 mL during the Final Month (the last 28 days prior to and including the Reference Day, which is defined as the last visit date during the Treatment Period (last treatment visit date) or the last dose date if there are evaluable alkaline hematin data after the last treatment visit date and prior to or on the last dose date), and * ≥ 50% reduction in MBL volume from Baseline to the Final Month. Participants who prematurely discontinued study drug due to "lack of efficacy," "requires surgery or invasive intervention for treatment of uterine fibroids," or "adverse events" were considered non-responders regardless of whether she meets the two aforementioned responder criteria or not.

    Time frame: Final Month (the last 28 days prior to and including the Reference Day), up to Month 6

Secondary outcomes

  1. Change From Baseline in MBL Volume to the Final Month

    Baseline MBL volume was defined as the mean of total MBL volume from all the qualified menstrual cycles during the Screening Period, in which the total MBL volume is from all validated and non-validated sanitary products and the MBL volume of validated sanitary products only (excluding non-validated sanitary products) was greater than 80 mL. The Reference Day is defined as the last visit date during the Treatment Period (last treatment visit date) or the last dose date if there are evaluable alkaline hematin data after the last treatment visit date and prior to or on the last dose date.

    Time frame: Baseline and Final Month (the last 28 days prior to and including the Reference Day), up to Month 6

  2. Percentage of Participants With Suppression of Bleeding at the Final Month

    Suppression of bleeding is defined as having 0 days of bleeding (spotting is allowed) during the Final Month with the interval starting from Study Day 11. The Reference Day is defined as the last visit date during the Treatment Period (last treatment visit date) or the last dose date if there are evaluable alkaline hematin data after the last treatment visit date and prior to or on the last dose date.

    Time frame: Final Month (the last 28 days prior to and including the Reference Day), up to Month 6

  3. Change From Baseline in MBL Volume to Month 6

    Baseline MBL volume was defined as the mean of total MBL volume from all the qualified menstrual cycles during the Screening Period, in which the total MBL volume is from all validated and non-validated sanitary products and the MBL volume of validated sanitary products only (excluding non-validated sanitary products) was greater than 80 mL.

    Time frame: Month 0 (Baseline), Month 6

  4. Change From Baseline in MBL Volume to Month 3

    Baseline MBL volume was defined as the mean of total MBL volume from all the qualified menstrual cycles during the Screening Period, in which the total MBL volume is from all validated and non-validated sanitary products and the MBL volume of validated sanitary products only (excluding non-validated sanitary products) was greater than 80 mL.

    Time frame: Month 0 (Baseline), Month 3

  5. Percentage of Participants With Baseline Hemoglobin <= 10.5 g/dL Who Have an Increase in Hemoglobin > 2 g/dL at Month 6

    Time frame: Month 0 (Baseline), Month 6

  6. Change From Baseline in MBL Volume to Month 1

    Baseline MBL volume was defined as the mean of total MBL volume from all the qualified menstrual cycles during the Screening Period, in which the total MBL volume is from all validated and non-validated sanitary products and the MBL volume of validated sanitary products only (excluding non-validated sanitary products) was greater than 80 mL.

    Time frame: Month 0 (Baseline), Month 1

07

Results

Posted Jun 30, 2020

Participant flow

Treatment Period
Participant flow — Treatment Period
MilestonePlaceboElagolixElagolix + E2/NETA
Started9495189
Completed7269148
Not completed222641
Post-Treatment Follow-Up Period
Participant flow — Post-Treatment Follow-Up Period
MilestonePlaceboElagolixElagolix + E2/NETA
Started142559
Completed91842
Not completed5717
Withdrew: Withdrawal by subject128
Withdrew: Lost to follow-up234
Withdrew: Other211
Withdrew: Required surgery/invasive intervention003
Withdrew: Non-compliance011

Outcome measures

PrimaryPercentage of Participants Meeting the Criteria for Responder

Percentage of responders, defined as participants who met the following conditions: * Menstrual blood loss (MBL) volume \< 80 mL during the Final Month (the last 28 days prior to and including the Reference Day, which is defined as the last visit date during the Treatment Period (last treatment visit date) or the last dose date if there are evaluable alkaline hematin data after the last treatment visit date and prior to or on the last dose date), and * ≥ 50% reduction in MBL volume from Baseline to the Final Month. Participants who prematurely discontinued study drug due to "lack of efficacy," "requires surgery or invasive intervention for treatment of uterine fibroids," or "adverse events" were considered non-responders regardless of whether she meets the two aforementioned responder criteria or not.

Time frame:
Final Month (the last 28 days prior to and including the Reference Day), up to Month 6
Reported as:
Number · percentage of participants
Percentage of Participants Meeting the Criteria for Responder
percentage of participantsPlaceboElagolixElagolix + E2/NETA
Percentage of Participants Meeting the Criteria for Responder10.576.976.5
Statistical analysis
  • Placebo vs Elagolix · Regression, Logistic · p = < 0.001 (The P value for test of difference is by pooling the results from a logistic regression model including treatment as the main effect and baseline MBL volume as a covariate in each data set from multiple imputation.) · Odds ratio (or): 28.73 · 95% CI 12.248 to 67.387
  • Placebo vs Elagolix + E2/NETA · Regression, Logistic · p = < 0.001 (The P value for test of difference is by pooling the results from a logistic regression model including treatment as the main effect and baseline MBL volume as a covariate in each data set from multiple imputation.) · Odds ratio (or): 28.31 · 95% CI 13.042 to 61.431
SecondaryChange From Baseline in MBL Volume to the Final Month

Baseline MBL volume was defined as the mean of total MBL volume from all the qualified menstrual cycles during the Screening Period, in which the total MBL volume is from all validated and non-validated sanitary products and the MBL volume of validated sanitary products only (excluding non-validated sanitary products) was greater than 80 mL. The Reference Day is defined as the last visit date during the Treatment Period (last treatment visit date) or the last dose date if there are evaluable alkaline hematin data after the last treatment visit date and prior to or on the last dose date.

Time frame:
Baseline and Final Month (the last 28 days prior to and including the Reference Day), up to Month 6
Reported as:
Least squares mean · mL
Change From Baseline in MBL Volume to the Final Month
mLPlaceboElagolixElagolix + E2/NETA
Change From Baseline in MBL Volume to the Final Month-4.3 ± 15.44-198.8 ± 15.44-168.8 ± 10.72
Statistical analysis
  • Placebo vs Elagolix · ANCOVA · p = < 0.001 (The P value for test of difference between each elagolix treatment group and placebo is by pooling the results from an ANCOVA model with treatment as the main effect and baseline MBL volume as a covariate in each dataset from multiple imputation.) · Ls mean of difference: -194.5
  • Placebo vs Elagolix + E2/NETA · ANCOVA · p = < 0.001 (The P value for test of difference between each elagolix treatment group and placebo is by pooling the results from an ANCOVA model with treatment as the main effect and baseline MBL volume as a covariate in each dataset from multiple imputation.) · Ls mean of difference: -164.6
SecondaryPercentage of Participants With Suppression of Bleeding at the Final Month

Suppression of bleeding is defined as having 0 days of bleeding (spotting is allowed) during the Final Month with the interval starting from Study Day 11. The Reference Day is defined as the last visit date during the Treatment Period (last treatment visit date) or the last dose date if there are evaluable alkaline hematin data after the last treatment visit date and prior to or on the last dose date.

Time frame:
Final Month (the last 28 days prior to and including the Reference Day), up to Month 6
Reported as:
Number · percentage of participants
Percentage of Participants With Suppression of Bleeding at the Final Month
percentage of participantsPlaceboElagolixElagolix + E2/NETA
Percentage of Participants With Suppression of Bleeding at the Final Month4.788.961.0
Statistical analysis
  • Placebo vs Elagolix · chi-square or Fisher's exact test · p = < 0.001 (The P value is calculated based on chi-square test (or Fisher's exact test if ≥ 20% of the cells have expected cell count \< 5).) · Between-group difference (%): 84.2 · 95% CI 75.99 to 92.37
  • Placebo vs Elagolix + E2/NETA · chi-square or Fisher's exact test · p = < 0.001 (The P value is calculated based on chi-square test (or Fisher's exact test if ≥ 20% of the cells have expected cell count \< 5).) · Between-group difference (%): 56.3 · 95% CI 47.77 to 64.91
SecondaryChange From Baseline in MBL Volume to Month 6

Baseline MBL volume was defined as the mean of total MBL volume from all the qualified menstrual cycles during the Screening Period, in which the total MBL volume is from all validated and non-validated sanitary products and the MBL volume of validated sanitary products only (excluding non-validated sanitary products) was greater than 80 mL.

Time frame:
Month 0 (Baseline), Month 6
Reported as:
Least squares mean · mL
Change From Baseline in MBL Volume to Month 6
mLPlaceboElagolixElagolix + E2/NETA
Change From Baseline in MBL Volume to Month 628.5 ± 16.68-223.7 ± 17.98-198.1 ± 11.89
Statistical analysis
  • Placebo vs Elagolix · mixed model repeated measures · p = < 0.001 (The P value is from mixed models repeated measures (MMRM) with treatment, month, and an interaction between treatment and month as fixed effect factors, and baseline MBL volume as a covariate comparing each elagolix treatment group with placebo.) · Ls mean of difference: -252.3
  • Placebo vs Elagolix + E2/NETA · mixed model repeated measures · p = < 0.001 (The P value is from mixed models repeated measures (MMRM) with treatment, month, and an interaction between treatment and month as fixed effect factors, and baseline MBL volume as a covariate comparing each elagolix treatment group with placebo.) · Ls mean of difference: -226.6
SecondaryChange From Baseline in MBL Volume to Month 3

Baseline MBL volume was defined as the mean of total MBL volume from all the qualified menstrual cycles during the Screening Period, in which the total MBL volume is from all validated and non-validated sanitary products and the MBL volume of validated sanitary products only (excluding non-validated sanitary products) was greater than 80 mL.

Time frame:
Month 0 (Baseline), Month 3
Reported as:
Least squares mean · mL
Change From Baseline in MBL Volume to Month 3
mLPlaceboElagolixElagolix + E2/NETA
Change From Baseline in MBL Volume to Month 3-14.2 ± 11.57-211.1 ± 11.96-200.3 ± 8.17
Statistical analysis
  • Placebo vs Elagolix · mixed model repeated measures · p = < 0.001 (The P value is from MMRM with treatment, month, and an interaction between treatment and month as fixed effect factors, and baseline MBL volume as a covariate comparing each elagolix treatment group with placebo.) · Ls mean of difference: -196.9
  • Placebo vs Elagolix + E2/NETA · mixed model repeated measures · p = < 0.001 (The P value is from MMRM with treatment, month, and an interaction between treatment and month as fixed effect factors, and baseline MBL volume as a covariate comparing each elagolix treatment group with placebo.) · Ls mean of difference: -186.1
SecondaryPercentage of Participants With Baseline Hemoglobin <= 10.5 g/dL Who Have an Increase in Hemoglobin > 2 g/dL at Month 6
Time frame:
Month 0 (Baseline), Month 6
Reported as:
Number · percentage of participants
Percentage of Participants With Baseline Hemoglobin <= 10.5 g/dL Who Have an Increase in Hemoglobin > 2 g/dL at Month 6
percentage of participantsPlaceboElagolixElagolix + E2/NETA
Percentage of Participants With Baseline Hemoglobin <= 10.5 g/dL Who Have an Increase in Hemoglobin > 2 g/dL at Month 620.840.050.0
Statistical analysis
  • Placebo vs Elagolix · chi-square or Fisher's exact test · p = 0.146 (The P value is calculated based on chi-square test (or Fisher's exact test if ≥ 20% of the cells have expected cell count \< 5).) · Between-group difference (%): 19.2 · 95% CI -5.99 to 44.32
  • Placebo vs Elagolix + E2/NETA · chi-square or Fisher's exact test · p = 0.017 (The P value is calculated based on chi-square test (or Fisher's exact test if ≥ 20% of the cells have expected cell count \< 5).) · Between-group difference (%): 29.2 · 95% CI 7.62 to 50.71
SecondaryChange From Baseline in MBL Volume to Month 1

Baseline MBL volume was defined as the mean of total MBL volume from all the qualified menstrual cycles during the Screening Period, in which the total MBL volume is from all validated and non-validated sanitary products and the MBL volume of validated sanitary products only (excluding non-validated sanitary products) was greater than 80 mL.

Time frame:
Month 0 (Baseline), Month 1
Reported as:
Least squares mean · mL
Change From Baseline in MBL Volume to Month 1
mLPlaceboElagolixElagolix + E2/NETA
Change From Baseline in MBL Volume to Month 1-2.1 ± 14.31-196.6 ± 14.74-127.0 ± 10.14
Statistical analysis
  • Placebo vs Elagolix · mixed model repeated measures · p = < 0.001 (The P value is from MMRM with treatment, month, and an interaction between treatment and month as fixed effect factors, and baseline MBL volume as a covariate comparing each elagolix treatment group with placebo.) · Ls mean of difference: -194.5
  • Placebo vs Elagolix + E2/NETA · mixed model repeated measures · p = < 0.001 (The P value is from MMRM with treatment, month, and an interaction between treatment and month as fixed effect factors, and baseline MBL volume as a covariate comparing each elagolix treatment group with placebo.) · Ls mean of difference: -125.0

Adverse events

Collected over From first dose of study drug through 6 months of treatment with a 30-day follow-up period for participants who did not enroll in the extension study (Study M12-816). Mean (SD) treatment exposure was 160.3 (51.75), 155.2 (65.19), and 158.7 (54.68) days for the Placebo, Elagolix, and Elagolix and E2-NETA arms, respectively. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/94 (0%)1/94 (1.1%)34/94 (36.2%)
Elagolix0/95 (0%)4/95 (4.2%)58/95 (61.1%)
Elagolix + E2-NETA0/189 (0%)7/189 (3.7%)80/189 (42.3%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventPlaceboElagolixElagolix + E2-NETA
ABORTION COMPLETEPregnancy, puerperium and perinatal conditions1/940/950/189
SMALL INTESTINAL OBSTRUCTIONGastrointestinal disorders0/941/950/189
CHOLELITHIASISHepatobiliary disorders0/941/951/189
APPENDICITISInfections and infestations0/941/950/189
PELVIC PAINReproductive system and breast disorders0/941/950/189
ANAEMIABlood and lymphatic system disorders0/940/951/189
HYPERTHYROIDISMEndocrine disorders0/940/951/189
CELLULITISInfections and infestations0/940/951/189
OBESITYMetabolism and nutrition disorders0/940/951/189
ANXIETYPsychiatric disorders0/940/951/189
Most frequent other events
Showing 10 of 11
Most frequent other events
EventPlaceboElagolixElagolix + E2-NETA
HOT FLUSHVascular disorders4/9441/9537/189
NIGHT SWEATSSkin and subcutaneous tissue disorders5/9424/9520/189
HEADACHENervous system disorders5/9413/9520/189
NAUSEAGastrointestinal disorders9/944/9514/189
NASOPHARYNGITISInfections and infestations8/944/9510/189
DYSMENORRHOEAReproductive system and breast disorders6/940/956/189
URINARY TRACT INFECTIONInfections and infestations5/942/9512/189
MOOD SWINGSPsychiatric disorders2/946/956/189
FATIGUEGeneral disorders5/943/9510/189
LIBIDO DECREASEDPsychiatric disorders2/943/9510/189

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboElagolixElagolix + E2/NETATotal
Mean42.5 ± 5.4342.2 ± 5.4142.5 ± 5.3342.4 ± 5.36
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboElagolixElagolix + E2/NETATotal
Female9495189378
Male0000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboElagolixElagolix + E2/NETATotal
Hispanic or Latino11173159
Not Hispanic or Latino8378158319
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboElagolixElagolix + E2/NETATotal
American Indian or Alaska Native0000
Asian1203
Native Hawaiian or Other Pacific Islander0022
Black or African American6366124253
White302759116
More than one race0033
Unknown or Not Reported0011
08

Study locations

105 sites
  • Alabama Clinical Therapeutics, LLC /ID# 152258
    Birmingham, Alabama 35235-3430, United States
  • Choice Research, LLC /ID# 150988
    Dothan, Alabama 36303, United States
  • Brown, Pearson, Guepet Gynecology /ID# 151020
    Fairhope, Alabama 36532, United States
  • Mobile, Ob-Gyn, P.C. /ID# 144294
    Mobile, Alabama 36608, United States
  • Mesa Obstetricians and Gynecol /ID# 149139
    Mesa, Arizona 85209, United States
  • Visions Clinical Research-Tucs /ID# 151017
    Tucson, Arizona 85712, United States
  • Core Healthcare Group /ID# 151016
    Cerritos, California 90703, United States
  • Diagnamics Inc. /ID# 152469
    Encinitas, California 92024, United States
  • HCP Clinical Research LLC /ID# 154434
    Huntington Beach, California 92646, United States
  • Alliance Research Centers /ID# 149752
    Laguna Hills, California 92653-3621, United States
  • University of California, Los Angeles /ID# 149760
    Los Angeles, California 90095, United States
  • Futura Research, Inc. /ID# 149759
    Norwalk, California 90650, United States
  • Farid Yasharpour MD Medical Co /ID# 149770
    San Fernando, California 91340, United States
  • Clinical Trial Investigators /ID# 152470
    Tustin, California 92780, United States
  • Bayview Research Group LLC /ID# 153799
    Valley Village, California 91607, United States
  • Emerson Clinical Research Inst /ID# 152348
    Washington, District of Columbia 20011, United States
  • Ideal Clinical Research Inc. /ID# 149757
    Aventura, Florida 33180, United States
  • Seffner Premier Health Care, P /ID# 167480
    Brandon, Florida 33510, United States
  • Olympian Clinical Research /ID# 149756
    Clearwater, Florida 33756, United States
  • KO Clinical Research, LLC /ID# 144299
    Fort Lauderdale, Florida 33316, United States
  • University of Florida /ID# 149751
    Gainesville, Florida 32610, United States
  • Solutions Through Adv Rch /ID# 151021
    Jacksonville, Florida 32256, United States
  • Meridien Research /ID# 167100
    Kenneth City, Florida 33709-3113, United States
  • Precision Research Org, LLC /ID# 144335
    Miami Lakes, Florida 33016-1501, United States
  • Invictus Clinical Research Group,LLC /ID# 141859
    Miami, Florida 33144, United States
  • Suncoast Clinical Research /ID# 149765
    New Port Richey, Florida 34652, United States
  • All Wmns HC of West Broward /ID# 144298
    Plantation, Florida 33324, United States
  • Oncova Clinical Research, Inc. /ID# 149764
    Saint Cloud, Florida 34769, United States
  • Physician Care Clin. Res., LLC /ID# 149766
    Sarasota, Florida 34239, United States
  • Qps-Mra, Llc /Id# 144325
    South Miami, Florida 33143, United States
  • Martin Health System Center /ID# 152263
    Stuart, Florida 34994, United States
  • University of South Florida /ID# 149754
    Tampa, Florida 33612, United States
  • Axcess Medical Research /ID# 149769
    Wellington, Florida 33414, United States
  • Virtus Research Consultant,LLC /ID# 144296
    Wellington, Florida 33414, United States
  • Paramount Research Solutions /ID# 149291
    Alpharetta, Georgia 30005, United States
  • Agile Clinical Research Trials /ID# 167074
    Atlanta, Georgia 30328, United States
  • Mount Vernon Clinical Res, LLC /ID# 144297
    Atlanta, Georgia 30328, United States
  • Atlanta Women's Research Inst /ID# 144303
    Atlanta, Georgia 30342, United States
  • Masters of Clinical Research, Inc. /ID# 167400
    Augusta, Georgia 30909, United States
  • Georgia Regents University /ID# 144295
    Augusta, Georgia 30912, United States
  • Meridian Clinical Research, LLC /ID# 149144
    Savannah, Georgia 31406-2675, United States
  • Gyn-Care, Inc. /ID# 149341
    Smyrna, Georgia 30080, United States
  • Atlanta Gynecology Research Institute /ID# 151014
    Suwanee, Georgia 30024-7159, United States
  • Womens Healthcare Assoc, DBA /ID# 149762
    Idaho Falls, Idaho 83404, United States
  • Advanced Clinical Research /ID# 149767
    Meridian, Idaho 83642, United States
  • University of Chicago /ID# 152257
    Chicago, Illinois 60637-1443, United States
  • Affinity Clinical Research /ID# 167119
    Oak Brook, Illinois 60523, United States
  • Center for Women's Research, Inc /ID# 144300
    Palos Heights, Illinois 60463-1440, United States
  • Women's Health Advantage /ID# 144301
    Fort Wayne, Indiana 46825, United States
  • The Iowa Clinic /ID# 150105
    West Des Moines, Iowa 50266, United States
  • PRN Professional Research Network of Kansas, LLC /ID# 152265
    Wichita, Kansas 67205, United States
  • Bluegrass Clinical Research /ID# 150103
    Louisville, Kentucky 40291, United States
  • Clinical Trials Management, LLC - Covington /ID# 144314
    Covington, Louisiana 70433, United States
  • Women Under Study, LLC /ID# 144312
    New Orleans, Louisiana 70125-1923, United States
  • Baltimore Suburban Health /ID# 154638
    Baltimore, Maryland 21208, United States
  • Womens Health Center /ID# 154209
    Glen Burnie, Maryland 21063, United States
  • Maryland Ctr for Sexual Health /ID# 149778
    Lutherville, Maryland 21093, United States
  • NECCR Fall River LLC /ID# 149584
    Fall River, Massachusetts 02720-2972, United States
  • Saginaw Valley Med Res Group /ID# 149768
    Saginaw, Michigan 48604, United States
  • Accent Clinical Trials /ID# 149753
    Las Vegas, Nevada 89106-4017, United States
  • Jersey Shore University Medical Center /ID# 149779
    Neptune, New Jersey 07753-4859, United States
  • Rowan University SOM /ID# 152697
    Stratford, New Jersey 08084, United States
  • Montefiore Medical Center /ID# 149582
    Bronx, New York 10461, United States
  • SUNY Downstate Medical Center /ID# 144311
    Brooklyn, New York 11203, United States
  • Manhattan Medical Research /ID# 167077
    New York, New York 10016-6023, United States
  • Weill Cornell Medicine /ID# 149585
    New York, New York 10032-3725, United States
  • Duplicate_Unified Women's Clinical Research-Fayetteville /ID# 149587
    Fayetteville, North Carolina 28304, United States
  • Unified Women's Clinical Research-Greensboro /ID# 149588
    Greensboro, North Carolina 27408, United States
  • Pinewest Ob-Gyn, Inc. /ID# 145671
    High Point, North Carolina 27262, United States
  • Eastern Carolina Women's Centr /ID# 144309
    New Bern, North Carolina 28562, United States
  • Wake Research Associates, LLC /ID# 144307
    Raleigh, North Carolina 27612, United States
  • Clinical Inquest Center Ltd /ID# 148728
    Beavercreek, Ohio 45432, United States
  • CTI Clinical Research Center /ID# 149761
    Cincinnati, Ohio 45212, United States
  • The Christ Hospital /ID# 150104
    Cincinnati, Ohio 45219, United States
  • Alpha Research Associates LLC /ID# 152471
    Dayton, Ohio 45417, United States
  • Comprehensive Womens Care /ID# 144306
    Westerville, Ohio 43081, United States
  • Family Medical Associates /ID# 145668
    Levittown, Pennsylvania 19056, United States
  • University of Pennsylvania /ID# 149586
    Philadelphia, Pennsylvania 19104-5502, United States
  • Clinical Research of Philadelphia, LLC /ID# 151015
    Philadelphia, Pennsylvania 19114, United States
  • Reading Hosp Clncl Trials Ofc /ID# 149583
    West Reading, Pennsylvania 19611, United States
  • Holston Medical Group /ID# 149763
    Bristol, Tennessee 37620-7346, United States
  • Chattanooga Medical Research /ID# 145667
    Chattanooga, Tennessee 37404, United States
  • Chattanooga Women for Women /ID# 167051
    Hixson, Tennessee 37343-3992, United States
  • The Jackson Clinic, PA /ID# 145670
    Jackson, Tennessee 38305, United States
  • The Womens Physician Group /ID# 144317
    Memphis, Tennessee 38104, United States
  • Access Clinical Trials, Inc. /ID# 167333
    Nashville, Tennessee 37203, United States
  • Lotus Gynecology /ID# 149140
    Austin, Texas 78703-1448, United States
  • Inquest Clinical Research /ID# 149755
    Baytown, Texas 77521-2415, United States
  • Texas Health Presbyterian Hosp /ID# 149142
    Dallas, Texas 75231, United States
  • Baylor College of Medicine /ID# 149141
    Houston, Texas 77030-3411, United States
  • The Woman's Hospital of Texas /ID# 144319
    Houston, Texas 77054, United States
  • Centex Studies, Inc. - Houston /ID# 150106
    Houston, Texas 77058, United States
  • BI Research Center /ID# 149143
    Houston, Texas 77084, United States
  • FMC Science /ID# 151802
    Lampasas, Texas 76550, United States
  • Willowbend Health and Wellness /ID# 144318
    Plano, Texas 75035, United States
  • Clinical Trials of Texas,Inc. /ID# 144322
    San Antonio, Texas 78229, United States
  • Center of Reproductive Medicin /ID# 167235
    Webster, Texas 77598, United States
  • Southampton Women's Health /ID# 152325
    Franklin, Virginia 23851, United States
  • Tidewater Physicians for Women /ID# 144321
    Norfolk, Virginia 23502, United States
  • Clinical Research Partners, LLC /ID# 144310
    Richmond, Virginia 23220-4459, United States

Showing the first 100 of 105 sites across 2 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Beck D, Winzenborg I, Liu M, Degner J, Mostafa NM, Noertersheuser P, Shebley M. Population Pharmacokinetics of Elagolix in Combination with Low-Dose Estradiol/Norethindrone Acetate in Women with Uterine Fibroids. Clin Pharmacokinet. 2022 Apr;61(4):577-587. doi: 10.1007/s40262-021-01096-w. Epub 2021 Dec 8. PubMed 34878624 ↗
  • Stewart EA, Archer DF, Owens CD, Barnhart KT, Bradley LD, Feinberg EC, Gillispie-Bell V, Imudia AN, Liu R, Kim JH, Al-Hendy A. Reduction of Heavy Menstrual Bleeding in Women Not Designated as Responders to Elagolix Plus Add Back Therapy for Uterine Fibroids. J Womens Health (Larchmt). 2022 May;31(5):698-705. doi: 10.1089/jwh.2021.0152. Epub 2021 Sep 28. PubMed 34582715 ↗
  • Muneyyirci-Delale O, Archer DF, Owens CD, Barnhart KT, Bradley LD, Feinberg E, Gillispie V, Hurtado S, Kim JH, Wang A, Wang H, Stewart EA. Efficacy and safety of elagolix with add-back therapy in women with uterine fibroids and coexisting adenomyosis. F S Rep. 2021 May 26;2(3):338-346. doi: 10.1016/j.xfre.2021.05.004. eCollection 2021 Sep. PubMed 34553161 ↗
  • Beck D, Winzenborg I, Gao W, Mostafa NM, Noertersheuser P, Chiuve SE, Owens C, Shebley M. Integrating real-world data and modeling to project changes in femoral neck bone mineral density and fracture risk in premenopausal women. Clin Transl Sci. 2021 Jul;14(4):1452-1463. doi: 10.1111/cts.13006. Epub 2021 Apr 8. Erratum In: Clin Transl Sci. 2022 Mar;15(3):799. doi: 10.1111/cts.13188. PubMed 33650259 ↗
  • Schlaff WD, Ackerman RT, Al-Hendy A, Archer DF, Barnhart KT, Bradley LD, Carr BR, Feinberg EC, Hurtado SM, Kim J, Liu R, Mabey RG Jr, Owens CD, Poindexter A, Puscheck EE, Rodriguez-Ginorio H, Simon JA, Soliman AM, Stewart EA, Watts NB, Muneyyirci-Delale O. Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids. N Engl J Med. 2020 Jan 23;382(4):328-340. doi: 10.1056/NEJMoa1904351. PubMed 31971678 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code

Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.

Data sharing details ↗ · www.abbvie.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2016 to primary completion in Feb 2018, 24 months.

Results were first posted in Jun 2020, 2 years 4 months after primary completion. A results delay was requested in Feb 2019.

Of 25 phase 3 interventional studies under Leiomyoma, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 41. This study's 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2016
First posted
Feb 25, 2016
StartActual
Feb 3, 2016
Primary completionActual
Feb 14, 2018
CompletionActual
Jan 23, 2019
Results delay requested
Feb 5, 2019
Results first posted
Jun 30, 2020
Last update
Jul 13, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02691494
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Feb 25, 2016
Start date
Feb 3, 2016
Primary completion
Feb 14, 2018
Completion
Jan 23, 2019
Results posted
Jun 30, 2020
Last update
Jul 13, 2021

Study contacts

AbbVie Inc.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Elagolix · Estradiol · Norethindrone Acetate

Start the discussion